Vogiatzi Maria G, Autio Karen A, Schneider Robert, Giardina Patricia J
Department of Pediatrics, The New York-Presbyterian Hospital/Weill Medical College of Cornell University, NY, USA.
J Pediatr Endocrinol Metab. 2004 Oct;17(10):1415-21. doi: 10.1515/jpem.2004.17.10.1415.
Low bone mass occurs frequently in the aging thalassemic population. However, limited information exists on bone mass in children with thalassemia major (TM) during their first decade of life.
Spinal bone mineral density (BMD) was measured by dual-energy X-ray absorptiometry (DEXA) in 18 children (age 5.8 +/- 1.5 yr; M:F 8:10) with TM on hypertransfusion and iron chelation therapy. Serial BMD measurements were available for 11 of the 18 children.
Weight and height z scores were 0.81 +/- 4.2 and -0.47 +/- 1.7 respectively. At the first BMD, four (22.2%) patients presented with BMD z scores less than -2.5, seven (38.8%) had BMD z scores between -1 and -2.5, while the remaining seven (38.8%) had normal BMDs (z score above -1). The mean decline of BMD z score was -0.38/year (p = ns). BMD z scores correlated with height z scores (p = 0.039), but not with liver enzymes, serum ferritin levels, or thalassemia genotypes.
Low bone mass is present in most children with TM despite hypertransfusion and optimal chelation, adequate growth and lack of endocrine complications.
低骨量在老年地中海贫血人群中很常见。然而,关于重型地中海贫血(TM)患儿生命最初十年骨量的信息有限。
采用双能X线吸收法(DEXA)测量了18例接受强化输血和铁螯合治疗的TM患儿(年龄5.8±1.5岁;男∶女为8∶10)的脊柱骨密度(BMD)。18例患儿中有11例进行了连续BMD测量。
体重和身高z评分分别为0.81±4.2和 -0.47±1.7。首次测量BMD时,4例(22.2%)患者的BMD z评分低于 -2.5,7例(38.8%)的BMD z评分在 -1至 -2.5之间,其余7例(38.8%)的BMD正常(z评分高于 -1)。BMD z评分的平均年下降率为 -0.38/年(p =无统计学意义)。BMD z评分与身高z评分相关(p = 0.039),但与肝酶、血清铁蛋白水平或地中海贫血基因型无关。
尽管进行了强化输血和优化螯合治疗,且生长正常且无内分泌并发症,但大多数TM患儿仍存在低骨量。